论文部分内容阅读
目的:探讨米非司酮治疗围绝经期功血的疗效及对子宫内膜癌高危人群的预防价值。方法:选择1998年8月～2006年4月223例围绝经期功血患者,每日口服米非司酮10 mg,共6个月,对比治疗前后子宫内膜厚度、激素变化,诱导进入绝经及血红蛋白恢复情况。结果:B超检查提示,治疗前后子宫内膜厚度比较,有统计学差异(P<0.05);治疗前后诊刮子宫内膜病检结果比较,差异有统计学意义(P<0.01);生殖激素:治疗前后E2、FSH、LH、P水平比较差异有统计学意义(P<0.05),睾酮(T)水平比较无统计学差异(P>0.05)。患者用药期间全部闭经,60例停药后平均37天月经恢复,163例停药后直接绝经;198例治疗后1个月血红蛋白恢复正常,25例治疗3个月血红蛋白恢复正常。结论:米非司酮治疗围绝经期功血安全有效,对子宫内膜癌高危人群使用可发挥其一级和二级预防作用。
Objective: To investigate the curative effect of mifepristone on peri-menopausal dysfunctional uterine bleeding and its preventive value to high-risk endometrial cancer patients. Methods: From August 1998 to April 2006, 223 cases of perimenopausal dysfunctional uterine bleeding were selected and treated with 10 mg of mifepristone daily for 6 months. The changes of endometrial thickness and hormone before and after treatment were compared to induce menopause And hemoglobin recovery. Results: The results of ultrasonography showed that the thickness of endometrium before and after treatment had statistical significance (P <0.05), and there was a significant difference between the two groups (P <0.01) There were significant differences in the levels of E2, FSH, LH and P between the two groups before and after treatment (P <0.05) and the levels of testosterone (T) were not statistically different (P> 0.05). All patients were amenorrhea during the medication, 60 cases of an average of 37 days after withdrawal of menstruation recovery, 163 cases of direct menopause after stopping; 198 cases of hemoglobin after 1 month returned to normal, 25 cases of 3 months hemoglobin returned to normal. Conclusion: Mifepristone is safe and effective in the treatment of peri-menopausal dysfunctional uterine bleeding. It can exert its primary and secondary preventive effects on high-risk endometrial cancer patients.